Climbing the mountain of acute decompensated heart failure: The EVEREST trials

JAMA

Volumn 297, Issue 12, 2007, Pages 1374-1376

  Yancy, Clyde W ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CALCIUM SENSITIZER; DIURETIC AGENT; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO; TOLVAPTAN; VASOPRESSIN ANTAGONIST; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; VASOPRESSIN RECEPTOR;

ACUTE DECOMPENSATED HEART FAILURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EDEMA; EDITORIAL; HEALTH CARE COST; HEART FAILURE; HUMAN; LUNG CONGESTION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ACUTE DISEASE; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; NOTE;

ACUTE DISEASE; BENZAZEPINES; CARDIOVASCULAR AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, VASOPRESSIN;

EID: 33947733219     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.12.1374     Document Type: Editorial

References (17)

1. Konstam MA, Gheorghiade M, Burnett JC Jr, et al; for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-1331.
2. Gheorghiade M, Konstam MA, Burnett JC Jr, et al; for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332-1343.
3. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
4. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE and PROACTIVE. Eur J Heart Fail. 2006;8:105-110.
5. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
6. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997;62:187-193.
7. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708.
8. Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics - 2007 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
9. Fonarow GC, Adams KF Jr, Abraham WT, et al; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
10. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70.
11. Adams KF Jr, Fonarow GC, Emerman CL, et al; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
12. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10-38.
13. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-683.
14. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
15. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-1791.
16. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
17. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.